Literature DB >> 24424040

Elevated systolic blood pressure in male GH transgenic mice is age dependent.

Adam Jara1, Chance M Benner, Don Sim, Xingbo Liu, Edward O List, Lara A Householder, Darlene E Berryman, John J Kopchick.   

Abstract

Acromegaly is associated with an increased incidence of cardiovascular disease. Transgenic mice expressing bovine GH (bGH) gene have previously been used to examine the effects of chronic GH stimulation on cardiovascular function. Results concerning systolic blood pressure (SBP) in bGH mice are conflicting. We hypothesized that these discrepancies may be the result of the various ages of the mice used in previous studies. In the current study, SBP was assessed monthly in male bGH mice from 3-12 months of age. Factors known to alter blood pressure were assessed during this time and included: levels of brain natriuretic peptide (BNP) and glucose homeostasis markers, and renal levels of angiotensin-converting enzyme 2 and endothelial nitric oxide synthase. Beginning at 6 months of age bGH had increased SBP compared with wild-type controls, which remained elevated through 12 months of age. Despite having increased blood pressure and cardiac BNP mRNA, bGH mice had decreased circulating levels of BNP. Additionally, bGH mice had an age-dependent decline in insulin levels. For example, they were hyperinsulinemic at 3 months, but by 11 months of age were hypoinsulinemic relative to wild-type controls. This decrease in insulin was accompanied by improved glucose tolerance at 11 months. Finally, both angiotensin-converting enzyme 2 and endothelial nitric oxide synthase expression were severely depressed in kidneys of 11-month-old bGH mice. These results indicate that elevated SBP in bGH mice is dependent on age, independent of insulin resistance, and related to alterations in both the natriuretic peptide and renin-angiotensin systems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24424040      PMCID: PMC3929738          DOI: 10.1210/en.2013-1899

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  64 in total

Review 1.  A case and review of acromegaly-induced cardiomyopathy and the relationship between growth hormone and heart failure: cause or cure or neither or both?

Authors:  Ernst R Schwarz; Praveen Jammula; Rajiv Gupta; Salvatore Rosanio
Journal:  J Cardiovasc Pharmacol Ther       Date:  2006-12       Impact factor: 2.457

2.  Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors.

Authors:  G Di Cola; M H Cool; D Accili
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

Review 3.  Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides.

Authors:  Toshio Nishikimi; Koichiro Kuwahara; Kazuwa Nakao
Journal:  J Cardiol       Date:  2011-02-05       Impact factor: 3.159

4.  Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly.

Authors:  J A McKnight; D R McCance; D R Hadden; L Kennedy; G Roberts; B Sheridan; A B Atkinson
Journal:  Clin Endocrinol (Oxf)       Date:  1989-10       Impact factor: 3.478

5.  Vascular remodeling in the growth hormone transgenic mouse.

Authors:  R J Dilley; S M Schwartz
Journal:  Circ Res       Date:  1989-11       Impact factor: 17.367

Review 6.  Regulation of atherogenesis by chemokines and chemokine receptors.

Authors:  Wuzhou Wan; Philip M Murphy
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2012-12-07       Impact factor: 4.291

7.  N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances.

Authors:  Mikkel Andreassen; Jens Faber; Henrik Vestergaard; Caroline Kistorp; Lars Østergaard Kristensen
Journal:  Clin Endocrinol (Oxf)       Date:  2007-05       Impact factor: 3.478

8.  Effect of growth hormone replacement therapy on plasma brain natriuretic peptide concentration, cardiac morphology and function in adults with growth hormone deficiency.

Authors:  I Lazúrová; M Pura; H Wagnerová; M Tajtáková; M Sedláková; L' Tomás; J Payer; P Hrúziková; P Vanuga; J Podoba; L' Trejbalová; V Popovic; M Koltowska-Häggström
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-07-17       Impact factor: 2.949

9.  Age-related changes in body composition of bovine growth hormone transgenic mice.

Authors:  Amanda J Palmer; Min-Yu Chung; Edward O List; Jennifer Walker; Shigeru Okada; John J Kopchick; Darlene E Berryman
Journal:  Endocrinology       Date:  2008-10-23       Impact factor: 4.736

10.  Growth hormone, inflammation and aging.

Authors:  Michal M Masternak; Andrzej Bartke
Journal:  Pathobiol Aging Age Relat Dis       Date:  2012-04-04
View more
  17 in total

1.  Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).

Authors:  Caitrin W McDonough; Oyunbileg Magvanjav; Ana C C Sá; Nihal M El Rouby; Chintan Dave; Amelia N Deitchman; Marina Kawaguchi-Suzuki; Wenbin Mei; Yong Shen; Ravi Shankar Prasad Singh; Mohamed Solayman; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; John G Gums; Amy Webb; Steven E Scherer; Wolfgang Sadee; Stephen T Turner; Rhonda M Cooper-DeHoff; Yan Gong; Julie A Johnson
Journal:  Circ Genom Precis Med       Date:  2018-04

2.  Differential impact of selective GH deficiency and endogenous GH excess on insulin-mediated actions in muscle and liver of male mice.

Authors:  Jose Cordoba-Chacon; Manuel D Gahete; Owen P McGuinness; Rhonda D Kineman
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-30       Impact factor: 4.310

3.  GH action influences adipogenesis of mouse adipose tissue-derived mesenchymal stem cells.

Authors:  Nicoleta C Olarescu; Darlene E Berryman; Lara A Householder; Ellen R Lubbers; Edward O List; Fabian Benencia; John J Kopchick; Jens Bollerslev
Journal:  J Endocrinol       Date:  2015-05-05       Impact factor: 4.286

4.  Deficiency of hypoxia inducible factor-1α promoted progression of diabetic nephropathy with hypertension.

Authors:  Yuejiang Jiao; Hongwei Jiang; Haibo Lu; Yiping Yang; Yanfang Zhang; Kun Zhang; Hui Liu
Journal:  Exp Ther Med       Date:  2018-08-20       Impact factor: 2.447

5.  Increased fibrosis: A novel means by which GH influences white adipose tissue function.

Authors:  Lara A Householder; Ross Comisford; Silvana Duran-Ortiz; Kevin Lee; Katie Troike; Cody Wilson; Adam Jara; Mitchell Harberson; Edward O List; John J Kopchick; Darlene E Berryman
Journal:  Growth Horm IGF Res       Date:  2017-12-20       Impact factor: 2.372

6.  Male bovine GH transgenic mice have decreased adiposity with an adipose depot-specific increase in immune cell populations.

Authors:  Fabian Benencia; Stephanie Harshman; Silvana Duran-Ortiz; Ellen R Lubbers; Edward O List; Lara Householder; Mawadda Al-Naeeli; Xiaoyu Liang; Lonnie Welch; John J Kopchick; Darlene E Berryman
Journal:  Endocrinology       Date:  2014-12-18       Impact factor: 4.736

Review 7.  STAT5a/b contribute to sex bias in vascular disease: A neuroendocrine perspective.

Authors:  Pravin B Sehgal; Yang-Ming Yang; Huijuan Yuan; Edmund J Miller
Journal:  JAKSTAT       Date:  2015-09-18

8.  Differential gene signature in adipose tissue depots of growth hormone transgenic mice.

Authors:  Silvana Duran-Ortiz; Jonathan A Young; Adam Jara; Elizabeth A Jensen; Reetobrata Basu; Edward O List; Yanrong Qian; John J Kopchick; Darlene E Berryman
Journal:  J Neuroendocrinol       Date:  2020-10-12       Impact factor: 3.627

9.  Cardiac-Specific Disruption of GH Receptor Alters Glucose Homeostasis While Maintaining Normal Cardiac Performance in Adult Male Mice.

Authors:  Adam Jara; Xingbo Liu; Don Sim; Chance M Benner; Silvana Duran-Ortiz; Yanrong Qian; Edward O List; Darlene E Berryman; Jason K Kim; John J Kopchick
Journal:  Endocrinology       Date:  2016-04-01       Impact factor: 4.736

10.  Insulin, IGF-1, and GH Receptors Are Altered in an Adipose Tissue Depot-Specific Manner in Male Mice With Modified GH Action.

Authors:  Rikke Hjortebjerg; Darlene E Berryman; Ross Comisford; Stuart J Frank; Edward O List; Mette Bjerre; Jan Frystyk; John J Kopchick
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.